雷贝拉唑在预防阿司匹林所致脑梗死患者上消化道黏膜损伤中的临床疗效观察  

Clinical Observation of Rabeprazole in Prevention of Upper Gastrointestinal Mucosal Injury in Patients with Cerebral Infarction Caused by Aspirin

作　　者：赵宏[1] 张成斌[2] ZHAO Hong;ZHANG Cheng-Bin(Department of Neurology,Second Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,233040,China)

机构地区：[1]蚌埠医学院第二附属医院神经内科,安徽蚌埠233040 [2]蚌埠医学院第二附属医院消化内科,安徽蚌埠233040

出　　处：《黑龙江医学》2022年第12期1470-1472,共3页Heilongjiang Medical Journal

基　　金：蚌埠医学院自然科学基金面上项目(BYKY18142)。

摘　　要：目的:探讨雷贝拉唑在预防阿司匹林所引起的上消化道粘膜损伤中的临床疗效。方法:选取蚌埠医学院第二附属医院2019年1月-2020年6月就诊神经内科的189例新发脑梗死患者,入院后常规完善幽门螺杆菌抗体(HP-IgG)检测,其中60例幽门螺杆菌阴性患者作为研究对象,将其随机分成观察组和对照组,每组各30例。观察组口服阿司匹林肠溶片联合雷贝拉唑钠肠溶片,对照组单独口服阿司匹林肠溶片,疗程90 d。比较两组患者治疗前后上消化道粘膜损伤情况以及抗血小板治疗效果,明确阿司匹林肠溶片联合雷贝拉唑钠肠溶片口服在预防脑梗死再发和上消化道粘膜损伤中的疗效和安全性。结果:经过90 d的临床用药观察,观察组内镜下评分为(0.60±0.62)分,对照组内镜下评分为(5.36±4.21)分,两组患者比较,差异有统计学意义(t=6.13,P<0.05)。观察组和对照组口服阿司匹林肠溶片7 d时血栓弹力图血小板抑制率分别为(94.15±8.69)%,(92.80±8.86)%;90 d时分别为(94.49±5.25)%,(92.43±5.44)%。两组患者比较,差异无统计学意义(P>0.05)。结论:口服阿司匹林肠溶片联合雷贝拉唑钠肠溶片能降低阿司匹林引起的上消化道粘膜损伤,且不影响阿司匹林抗血小板疗效。Objective:To investigate the clinical effect of rabeprazole in the prevention of upper gastrointestinal mucosal injury caused by Aspirin.Methods:A total of 189 patients with new-onset cerebral infarction who visited the neurology department in the hospital from January 2019 to June 2020 were selected.After admission,the Helicobacter pylori antibody(HP-IgG)test was routinely improved.Among them,60 Helicobacter pylori-negative patients were selected as the research objects,and they were randomly divided into observation group and control group,with 30 cases in each group.The patients in the observation group were given oral aspirin enteric-coated tablets combined with rabeprazole sodium enteric-coated tablets,while the patients in the control group were given oral aspirin enteric-coated tablets alone for 90 d.The upper gastrointestinal mucosal injury and antiplatelet treatment effect were compared between the two groups of patients before and after treatment.The efficacy and safety of aspirin enteric-coated tablets combined with rabeprazole sodium enteric-coated tablets in the prevention of recurrent cerebral infarction and upper gastrointestinal mucosal injury was clarified.Results:After 90 days of clinical medication observation,the endoscopic score of the observation group was(0.60±0.62)points,and the endoscopic score of the control group was(5.36±4.21)points,and the difference between the two groups was statistically significant(t=6.13,P<0.05).The thromboelastography platelet inhibition rate of patients in the observation group and the control group after oral administration of aspirin enteric-coated tablets for 7 d was(94.15±8.69)%,(92.80±8.86)%,and(94.49±5.25)%,(92.43±5.44)%at 90 d,respectively.There was no statistically significant difference between the two groups(P>0.05).Conclusion:Oral aspirin enteric-coated tablets combined with rabeprazole sodium enteric-coated tablets can reduce the mucosal damage of upper digestive tract caused by aspirin without affecting the anti-platelet effect of aspirin.

关 键 词：脑梗死 阿司匹林 雷贝拉唑 上消化道粘膜损伤 

分 类 号：R743.3[医药卫生—神经病学与精神病学]